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Abstract
Objective: Published studies demonstrate that diagnosis with Type 2 diabetes (T2DM) places patients at risk of severe symptoms 
and increased mortality from COVID-19. The literature was reviewed to understand emerging evidence. Method: A review of pub-
lished studies on COVID-19 in patients with diabetes was conducted to identify the needs and optimal practice for the local pop-
ulation diagnosed with diabetes at risk of COVID-19. Key Findings: The combined sample was n=18746 where all patients were 
diagnosed with T2DM and COVID-19. The severity of symptoms was reported in n=7646. Most reported were fever, (32%) cough 
(26%), and chest tightness (8%). The causes of death were reported in n=3260. The main causes of death were: COVID-19 (76%), 
acute respiratory distress (5%). Other comorbidities were reported in n= 6968. The most reported comorbidities were hypertension 
(38%), cardiovascular (10%), and pulmonary disease (3%). Other risk factors were reported in n= 6968. Those most reported were 
diabetes, (80%) cardiovascular abnormalities (10%), hyperglycemia not previously diagnosed as diabetes (9%). The reported effects 
of antidiabetic medications on COVID-19 disease were reviewed for emerging evidence. Conclusions: Published studies underline 
the importance of maintaining weight, glycemic control, good hydration, and exercising as much as possible. Patients need to be 
informed to present to hospital promptly if developing COVID-19 symptoms. Normal T2DM therapy can be maintained in patients 
with no, or mild, symptoms. On presentation to hospital with severe COVID-19 disease, diabetes control maybe maintained with 
insulin, concurrent with hydration and metabolic parameters maintenance until the patient is recovered.
Keywords: Coronavirus, COVID-19, Diabetes Medications, Type 2 Diabetes.
a high-grade fever, a new or continuous cough, 
myalgia, gastrointestinal symptoms, and a 
loss or change in taste or smell [3]. They range 
from mild, to severe potentially life-threaten-
ing, causing hospitalization with pneumonia, 
acute respiratory distress syndrome (ARDS), 
multi-organ failure, and death [4].
Studies have described those with obe-
sity, diabetes, and pre-existing cardiovascular 
conditions as ‘at risk groups’ and they were 
the basis of the recommendations on shielding 
from the World Health Organisation (WHO) 
[5]. Type 2 diabetes (T2DM) was one of the con-
ditions classed as a risk factor to experience 
severe COVID-19 symptoms with a higher death 
rate especially in patients with poor glycemic 
control [6]. 
Introduction
The disease caused by the novel coro-
navirus SARS-Cov-2 (COVID-19) is one of the 
fastest spreading respiratory system transmit-
ted conditions, and is currently responsible 
for 13,141,232 cases with 7,660,786 recovered 
and 573,344 deaths globally [1]. The disease 
was declared a pandemic, triggering wide-
spread simultaneous lockdowns around the 
world, with a fluctuating mortality rate around 
the globe [2]. Currently there is no cure for 
COVID-19, with a number of pharmacological 
treatments currently undergoing clinical trials. 
The virus enters the body via the respiratory 
system causing a range of symptoms including 
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COVID-19. Severity of symptoms was reported in 
n=7646, and the most reported symptoms were 
fever, (32%) cough (26%), and chest tightness 
(8%). Causes of death were reported in n=3260 by 
Huang et al, [4], Zhu et al [6], and Roncon et al [8]. 
The main causes of death were: COVID-19 (76%) 
and acute respiratory distress (ARD) (5%). Other 
comorbidities were reported in n= 6968 by Huang 
et al [4], Desai et al [11], and Zhou and Tan [12]. 
The most reported comorbidities were hyperten-
sion (38%), cardiovascular (10%), and pulmonary 
disease (3%). Other risk factors were reported 
in n= 6968 by Huang et al [4], Desai et al [11], and 
Zhou and Tan [12]. The most reported risk factors 
were diabetes, (80%) cardiovascular abnormal-
ities (10%), hyperglycemia not previously diag-
nosed as diabetes (9%).
Diabetes medications were continued in 
n= 3185 and stopped in n= 15561 patients. Some 
medications used to treat diabetes were reported 
to contribute to poorer outcomes, if risk mitiga-
tion was not considered [15]. The authors con-
cluded that metformin was found to contribute 
to dehydration leading to lactic acidosis and 
acute kidney injury. They also concluded that the 
sodium-glucose-co- transporter 2 inhibitors (e.g., 
canagliflozin, dapagliflozin, and empagliflozin) 
should not be initiated or continued during the 
COVID-19 infections as, in addition to increasing 
the risk of dehydration and acute kidney injury, 
they can cause ketoacidosis. Bornstein et  al [15] 
stated that glucagon-like peptide-1 receptor 
Method
A literature search was conducted using 
ScienceDirect®, Google® scholar and PubMed®. 
The search terms used were <coronavirus>, <dia-
betes> and <type 2 diabetes>. The search was lim-
ited to 2019 and 2020 (Fig 1). A total of 10 studies 
were analyzed.
All articles were screened and reviewed to 
fit the criteria to assess the association between 
T2DM and COVID-19 (Appendix 1). 
Owing to the lack of randomized controlled 
trials, it was not possible to combine data from all 
studies for meta-analysis, so only a narrative review 
was possible on the information available (Table 1).
Results 
All patients reported in the studies 
selected had been diagnosed with T2DM and 
COVID-19; there were four domains selected to 
measure the studies risk of bias score:
1. The study reported on symptoms severity.
2. The study reported on causes of death.
3. The study reported on one or more other risk 
factors e.g., hypertension, age, obesity, etc.
4. Diabetes medication continued.
The combined sample was n=18746 where 
all patients were diagnosed with T2DM and 
Articles identified through search  
(n=2630) 
Articles further reviewed based on clinical 
conditions reviewed (n=130) 
Articles excluded based on clinical 
conditions reviewed (n=2500) 
Articles screened (n=2630) 
Articles with full access (n=10) 
Figure 1: Inclusion and exclusion criteria of literature used.
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patients with COVID-19 and pre-existing T2DM. 
In their retrospective multi-center study, they 
concluded that T2DM is a major co-morbidity of 
COVID-19. Zhu et al [6] explained that glycemic 
control in T2DM is an important factor in how an 
individual is impacted with COVID-19 and when 
poor, increased the likelihood of a severe presen-
tation compared to those with no diabetes. Their 
study also revealed that T2DM patient required 
more time in intensive care units compared to 
non-diabetic patients. A gender difference was 
identified with males with T2DM at higher risk 
than females. Paland Bhadada [2] discussed 
the interaction between the two diseases and 
reviewed how T2DM placed individuals at a disad-
vantage. They found a clear relationship between 
agonists (e.g., insulin glargine with lixsenatide, 
dulaglutide, exenatide-extended release, lira-
glutide, lixisenatide, and semaglutide) can be 
continued subject to monitoring and correcting 
dehydration. Dipeptidyl peptidase-4 inhibitors 
(e.g., alogliptin, linagliptin, saxagliptin, and sita-
gliptin) were generally well tolerated and could 
be continued [15]. Lastly, they reported that insu-
lin was found to be the most beneficial and best 
tolerated, and should always be continued. 
Narrative analysis
Zhu et al [6] examined the associa-
tion between glycemic control and outcome in 
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the two conditions and on how they combine to 
precipitate a severe outcome in response to the 
COVID-19 infection. They hypothesized that 
the interaction occurs because of the “exager-
ated pro-inflammatory cytokine response and low 
expression of angiotensin-converting  enzyme 2 
(ACE2)” enhancing the severity of the  symptoms 
caused by the virus. They also explain how SARS-
Cov-2 causes worsening glycemic control. This 
is postulated to be due to SARS-Cov-2 mediated 
damage to pancreatic beta cells causing “auge-
mentation of insulin resistance through cytokines 
and ferritin A and hypokalemia” [2]. The study by 
Singh and Singh [16] supported Banerjeeh et al 
[17] who focused on the relationship between 
poor glycemic control and the increased risk of 
severe presentation of COVID-19 symptoms. 
Huang et al [4] concluded that COVID-19 
pneumonia was both more severe and more 
often fatal in T2DM patients than in non- diabetic 
patients. They described how other risk factors 
alongside T2DM such as hypertension, partic-
ularly when influenced by age, could further 
worsen the patient outcomes [4]. Zhang et al [9] 
also reported that patients with uncontrolled 
T2DM were more susceptible to COVID-19 infec-
tion, with higher mortality and severity of 
symptoms. 
Bouhanick et al [18] stated that “whilst 
diabetes would not systemically increase the likeli-
hood of being infected with COVID-19, once infected 
patients with diabetes are likely to develop a severe 
form of the disease”. The authors also high-
lighted the association of T2DM medication and 
how it may impact the severity in symptoms 
of COVID-19. They explain how dipeptidylpep-
tidase-4 inhibitors can “via the inflammatory 
effect, play arole in the course of the infection or 
in the occurrence of its complications” [18]. The 
authors highlighted other T2DM medications 
that should be used with caution or discontin-
ued in patients with COVID-19. These included 
ipeptidylpeptidase-4 inhibitors, glucagon like 
peptide-1 agonists, sodium-glucose co-trans-
porter 2 inhibitor, and metformin [18]. Mukher-
jee et al [19] concluded that “pioglitazone has more 
potential for benefit than harm and can be continued 
in people with T2DM and mild/moderate COVID-19” 
unless contraindicated in the specific patient. 
The pharmacology of the thiazolidinediones is 
said to play a vital role against COVID-19 through 
the moderation of host inflammatory responses 
that are driving hyperinflammation [19].
Bornstein et al [15] explained the nature 
and complexity of diabetes and how it is gener-
ally a primary risk factor for severe pneumonia 
in up to 50% in a diabetic patients compared to 
non-diabetic patients. The increased risk of 
infection is postulated to be due to “defects in 
innate immunity affecting phagocytosis, neutro-
phil chemotaxis and cell mediated immunity” [15]. 
In a meta-analysis, Kumar et al [7] described a 
strong correlation between diabetes and severe 
COVID-19 symptoms, from the pooled data of 
16,003 patients, leading to a two-fold increase 
in mortality and severity of COVID-19 as com-
pared to non-diabetics. Roncon et al [8] further 
explained that the diabetic patient is at higher 
risk of ICU admission, poor short-term out-
come, and poor survival rate due to exhibit-
ing deteriorating, disabling, severe symptoms. 
Raoufi et al [10] demonstrated that the chest 
computed tomography score did not show a sta-
tistically significant difference between the two 
groups. 
Age is reported to impact outcome. Desai 
et al [11] pooled data on various age groups to 
understand the effect on patients with COVID-19 
and T2DM. Their results revealed older patients 
showed an increased chance both of contracting 
COVID-19 and experiencing greater severity of 
symptoms. They reported that a patient, mean 
age <50 had a 9% chance of contracting COVID-19 
compared to 13.2% for >50 years of age. They also 
considered comorbidities such as cardiovascu-
lar complications, and reported that increasing 
comorbidities alongside age may further impact 
T2DM / COVID-19 patients. The retrospective 
study of Guo et al [13] (n=174) found patients 
with T2DM were at a higher risk of severe pneu-
monia compared to patients without other co- 
morbidities. Patients were screened with chest 
computed tomography (CT) alongside other 
treatment measures. They determined that 24 
of their 174 patients were at higher risk of pneu-
monia and “excessive uncontrolled inflammatory 
responses” [13]. They concluded such patients 
required closer attention and were to be reviewed 
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accordingly due to their potential for rapid 
deterioration. 
Zhou and Tan [12] reviewed the records of 
881 patients concluding that diabetes and hyper-
glycemia can lead to higher secondary infection 
risks and mortality and therefore, tight glycemic 
control is essential in COVID-19 patients. Wang 
et al [14], in a retrospective study of 132 patients, 
found the mortality rate was higher in patients 
with T2DM by 27.7% and that high HbA1c levels 
were associated with inflammation, hyperco-
agulability, and low oxygen saturations. They 
emphasized the importance of measuring HbA1c 
levels post hospital admission to improve the 
prognosis of COVID-19 [14]. They also explained 
how COVID-19 potentially caused abnormal beta 
cell damage and insulin resistance causing blood 
glucose levels above their baseline in all patients.
Antidiabetic medication and COVID-19
Medications used to treat diabetes can 
lead to further deterioration in COVID-19 due to 
dehydration and renal injury. Banerjee et al [17] 
highlighted how the pandemic may have had an 
impact on glycemic control; reduced physical 
activity, more chance of eating at home and of 
consuming high energy take-away food affecting 
weight and consequently their diabetes [17].
Bouhanick et al [18] reviewed the phar-
macological characteristics of T2DM treatment 
and the linkage to their effect on COVID-19. They 
discussed dipeptidyl peptidase-4 (DPP-4) inhibi-
tors and the potential increased risk of infection 
through stimulating an ‘inflammatory immune 
response through modifying the production of 
several cytokines and chemokines’ [18]. They 
noted that other studies agreed that DPP-4 inhib-
itors in T2DM patients, particularly sitagliptin, 
increased the risk of upper respiratory tract and 
lower urinary tract infections.
Nakhleh and Shehadeh [20] agreed that 
T2DM medications may have deleterious effects 
on patients presenting with COVID-19. How-
ever, they also noted how some T2DM treatment 
may offer a protective role in COVID-19 related 
lung injury [20]. Insulin is an effective treat-
ment to continue in diabetic patients positive 
for COVID-19 as it inhibits the production of 
pro- inflammatory factors preventing acute lung 
injury. It also reduces the risk of developing dia-
betic ketoacidosis or hyperglycemic hyperos-
molar states preventing further deterioration 
of any acute lung injury and acute respiratory 
 distress [20].
Bornstein et al [15] stated that biguanides 
and SGLT-2 inhibitors should be withheld in 
patients with severe symptoms of COVID-19 to 
prevent the risk of metabolic decompensation 
[15]. They recommend that after cessation, insu-
lin should be used for acute control. Conversely, 
regarding the DDP-4 inhibitors, Bornstein et al 
[15] differed from Bouhanick et al [18] by con-
cluding they believed there was no convincing 
evidence to suggest DDP-4 inhibitors should be 
discontinued.
Ursini et al [21] focused on biguanides in 
COVID-19 patients. Their article on “COVID-19 
and diabetes: Is metformin a friend or foe” 
describes how metformin and other medica-
tions such as pioglitazone and liraglutide may 
play a role in promoting the SARS-Cov-2 virus 
entry into host cells, they are said to ‘work syn-
ergistically to increase the angiotensin convert-
ing enzyme-2 availability in the respiratory tract 
promoting SARS-Cov-2 infection’ [21]. On the 
other hand, the author expounds how these med-
ications may be advantageous in maintaining the 
optimal management of glycemic control and 
therefore need to be monitored to assess whether 
they are beneficial to be continued in patients 
who are positive COVID-19 [21].
A scoping review by Wicaksana et al [22] 
focused on the pharmacological management of 
T2DM patients during the pandemic. They also 
noted the importance of glycemic control and 
the prevention of hypoglycemia. They advised 
that adjustment of ‘sulfonylurea and insulin 
dose may be necessary to prevent hypoglycemia’ 
and should be handled with caution in elderly 
patients as they are more likely to have deteri-
orating glycemic control. They also explained 
the importance of close glycemic control during 
the COVID-19 pandemic due to the restrictions 
imposed;  the social distancing and lockdown 
affecting individual weight, health, and men-
tal state causing poorer glycemic control, and 
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current evidence. Clearly diabetes and  particularly 
T2DM are risk factors for worsening prognosis in 
COVID-19. Based upon the above we believe the 
current understanding of the evidence is:
1. Patients diagnosed with T2DM in lockdown 
need to the best of their ability, to maintain 
good weight, good glycemic control, good 
hydration, and remain physically active. 
2. Practitioners should provide information 
on the importance of early presentation to 
healthcare providers if COVID-19 symptoms 
are developing.
3. Following the treating practitioner’s direc-
tions where possible, but taking note of 
the findings from previous studies. This 
suggests most patients with no symptoms 
or only mild symptoms of COVID-19 can 
maintain their normal therapy in T2DM 
patients.
4. Patients with severe COVID-19 symptoms, 
on presentation to hospital, most probably 
should have their oral therapy withheld 
and replaced by insulin while hydration and 
metabolic parameters are monitored until 
the patient has recovered.
5. This, like all other aspects of COVID-19 man-
agement, remains a fast-moving field and 
advice may change as more information 
emerges.
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pressure on staff in hospitals overloaded with 
Covid admissions [22].
Singh and Khunti [23] presented a concise 
table on anti-diabetic medications that may have 
a deleterious effect on patients diagnosed with 
COVID-19. The table showed that Metformin, 
Pioglitazone, Sulfonylurea, DPP-4 inhibitors, 
SGLT-2 inhibitors, and GLP-1 receptor agonists 
can all be continued in patients with mild to mod-
erate COVID-19 disease but should be withheld in 
those presenting with severe symptoms, whilst 
insulin may be continued at any stage [23].
Mukherjee et al [19] analyzed the use of 
pioglitazone in patients with COVID-19. They 
explained how pioglitazone had potential for 
more benefit than harm and could be contin-
ued as advised also for mild/moderate COVID-19 
disease.
It appears clear that tight glycemic con-
trol appears advantageous, but must be weighed 
against the risk of precipitating hypoglycemic 
episodes.
Limitations
COVID-19 is an extremely fast-moving 
field, and it is important to try to learn lessons 
as they emerge. However, most of the studies 
reported collected data in the early phase of the 
epidemic when many health services were over-
loaded and under pressure, whilst emerging data 
was constantly modifying policies and practices. 
It quickly became clear that T2DM is a major risk 
factor for severe presentations of COVID-19, and 
it is important that pharmacists learn the les-
sons of early experience in relation to diabetes 
and anti-diabetic drugs. This review presents and 
summarizes the information available at the time 
of submission. 
Conclusion
Managing COVID-19 disease continues to 
follow emerging evidence which appears almost 
daily, but it is essential to pause and try to review 
the best information available to date in order to 
adapt and try to ensure our management reflect the 
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